WO2020242199A1 - Procédé de production d'un conjugué immunogène du sérotype 23f de streptococcus pneumoniae - Google Patents

Procédé de production d'un conjugué immunogène du sérotype 23f de streptococcus pneumoniae Download PDF

Info

Publication number
WO2020242199A1
WO2020242199A1 PCT/KR2020/006863 KR2020006863W WO2020242199A1 WO 2020242199 A1 WO2020242199 A1 WO 2020242199A1 KR 2020006863 W KR2020006863 W KR 2020006863W WO 2020242199 A1 WO2020242199 A1 WO 2020242199A1
Authority
WO
WIPO (PCT)
Prior art keywords
serotype
carrier protein
polysaccharide
conjugate
activated
Prior art date
Application number
PCT/KR2020/006863
Other languages
English (en)
Korean (ko)
Inventor
신진환
김성현
김훈
안경준
Original Assignee
에스케이바이오사이언스 주식회사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에스케이바이오사이언스 주식회사 filed Critical 에스케이바이오사이언스 주식회사
Publication of WO2020242199A1 publication Critical patent/WO2020242199A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins

Definitions

  • Streptococcus pneumoniae Infection with the bacteria Streptococcus pneumoniae can cause several types of diseases, such as pneumonia (inflammation of the lungs), otitis media (inflammation of the middle ear), and meningitis (inflammation of the membranes surrounding the brain and spinal cord).
  • Streptococcus pneumoniae is a major causative agent of pneumonia. In addition, it causes invasive diseases such as sepsis, bacteremia, and meningitis.
  • the mortality rate from pneumonia in 2014 was 23.7 per 100,000 people, an increase of 11% compared to 2013, and an increase of 2.8 times compared to 2015, and the mortality rate due to pneumonia continued to increase. Showed a trend.
  • WHO WHO in 2012, 476,000 children under the age of 5 who were HIV-negative worldwide died from infections caused by Streptococcus pneumoniae in 2008, accounting for 5% of the causes of death for infants and young children under the age of 5.
  • the Streptococcus pneumoniae is encapsulated with a chemically linked polysaccharide that confers serotype specificity. This is called a capsule, a thick mucous layer that surrounds Streptococcus pneumoniae, and is used to defend itself or attach it to a specific surface.
  • the capsular polysaccharide has been widely used in immunology for many years for the prevention of Streptococcus pneumoniae disease. There are approximately 90 known Streptococcus pneumoniae serotypes, and the capsular membrane not only protects the inner surface of the Streptococcus pneumoniae from complement, but is itself an incomplete immunogen, so the capsular membrane is in the Streptococcus pneumoniae.
  • Streptococcus pneumoniae serotype 23F is known to exhibit high distribution in pediatric and adult pneumococcal-invasive patients. However, there are still difficulties in producing vaccines that can effectively prevent infection by Streptococcus pneumoniae with serotype 23F.
  • a vaccine using a conjugate made by conjugating a polysaccharide and a protein carrier has problems such as reduction in the size of the polysaccharide due to oxidation in the process of conjugation of the polysaccharide, or a low binding rate between the polysaccharide and the protein carrier. have.
  • the present invention is to provide a vaccine of Streptococcus pneumoniae serotype 23F.
  • An object of the present invention is to provide a method in which the capsular polysaccharide of Streptococcus pneumoniae serotype 23F maintains the size of a conjugate conjugated to a carrier protein and induces immunity.
  • An object of the present invention is to provide a method for preparing a conjugate with a small reduction in size of the capsular polysaccharide of Streptococcus pneumoniae serotype 23F.
  • the conjugate prepared by the method for preparing the conjugate is to be provided as an immunogenic composition.
  • the present invention is to provide a conjugate capable of preventing or treating diseases caused by Streptococcus pneumoniae serotype 23F, and to provide the conjugate for vaccine use.
  • the present invention relates to a method for preparing a Streptococcus pneumoniae serotype 23F conjugate.
  • the present invention provides a method for preparing a conjugate of a capsular polysaccharide of Streptococcus pneumoniae serotype 23F and a carrier protein.
  • the activated S. pneumoniae serotype 23F capsular polysaccharide decreases in size and is effective for conjugation. It provides a method of preparing a conjugate of S. pneumoniae serotype 23F and a carrier protein capable of obtaining a polysaccharide of.
  • An embodiment of the present invention is to provide an activated polysaccharide having a size of about 50 to 60% of the size of the natural 23F serotype polysaccharide.
  • the activated polysaccharide may have a constant size of about 300 kDa.
  • One embodiment of the present invention can provide a method of maintaining the size of about 50 to 60% of the polysaccharide of the natural 23F serotype.
  • activated polysaccharide refers to "activated S. pneumoniae serotype 23F polysaccharide", and refers to a polysaccharide chemically modified to form a reactive group in the polysaccharide chain. Activated polysaccharides do not necessarily mean that all available activation sites have been chemically modified. Activated saccharides can be understood to refer to capsular polysaccharides subjected to oxidation treatment, for example, and can be understood to mean polysaccharides in a state before conjugation of capsular polysaccharides to carrier proteins.
  • the capsular polysaccharide subjected to the oxidation treatment may be further subjected to a lyophilization step, and in this case, it may be understood to mean a polysaccharide in a state before conjugation with a protein after lyophilization.
  • the conjugate of S. pneumoniae may include the following steps.
  • Serotype 23F polysaccharides from which the conjugates of the present invention are prepared can be prepared using purification procedures known to those skilled in the art (see, eg, US Patent Application Publication No. 2008/0286838, etc.). It can also be produced using synthetic protocols. Typically capsular polysaccharides are prepared by growing each serotype 23F in a medium (eg, soy-based medium), and the polysaccharide can then be prepared from the bacterial culture. In one embodiment of the present invention, the capsular polysaccharide can be purified using purification techniques known in the art.
  • the purified serotype 23F polysaccharide may react with an oxidizing agent in a buffer solution.
  • the buffer may be preferably deionized water or acetic acid/sodium acetate (NaOAc), and most preferably, acetic acid/sodium acetate (NaOAc) may be used.
  • NaOAc acetic acid/sodium acetate
  • the inventors of the present invention confirmed that the yield of the conjugate can be improved and the size of the polysaccharide can be adjusted according to the characteristics of the buffer solution used in the process of activation of the polysaccharide, and the present invention was completed.
  • acetic acid/sodium acetate (NaOAc) buffer when used, a phenomenon in which the size of the polysaccharide rapidly decreases in the oxidation process may be less observed, and the conjugation yield of the polysaccharide and the carrier protein is improved, thereby ultimately resulting in immunogenicity. Can be improved. This effect is also seen in high concentration buffers above 100 mM.
  • the acetic acid/sodium acetate (NaOAc) buffer may have a concentration of 1 to 550 mM, a concentration of 5 to 540 mM, a concentration of 8 to 520 mM, or a concentration of 9 to 510 mM. It may preferably have a concentration of 10 to 500mM.
  • the pH in step (i) is pH 2.5-8, pH 3-6, or pH 4-5, or pH 4.5.
  • the pH 4.5 acetic acid/sodium acetate (NaOAc) buffer has a concentration of 1 to 550 mM, it may be advantageous in achieving the object of the present invention.
  • the inventors of the present invention confirmed that the yield of the conjugate can be improved and the size of the polysaccharide can be adjusted according to the molar equivalent of the oxidizing agent along with the properties of the buffer solution used in the process of activating the polysaccharide.
  • the oxidizing agent includes sodium periodate, and periodate and periodic acid may also be included as an oxidizing agent of the present invention.
  • periodate oxidizes adjacent hydroxyl groups to form carbonyl or aldehyde groups, causing decomposition of C-C bonds.
  • the term'reacting an antigen with periodate' includes the oxidation of adjacent hydroxyl groups by periodate.
  • the inventors of the present invention are preferably 0.07 to 0.23, 0.01 to 0.2, 0.015 to 0.19, 0.02 to 0.18, 0.05 To 0.17, 0.1 to 0.165 or 0.16 molar equivalent of periodate may be reacted to activate it.
  • the size of the polysaccharide can be obtained in an appropriate range. The above range is preferred for the purposes of the present invention.
  • the size change rate of activated S. pneumoniae serotype 23F is reduced, including the following steps, S. pneumoniae serotype 23F and a transporter. It provides a method of preparing a conjugate of a protein.
  • deionized water may be used instead of the sodium acetate (NaOAc) buffer of step (i).
  • the average molecular weight may be 100kDa or more, 200kDa or more, 300kDa or more, 400kDa or more, 500kDa or more. Preferably, for the purposes of the present invention, it may have a size of 300 to 500 Da.
  • MALLS technology is well known in the art. MALLS analysis can be performed using an Ultrahydrogel analytical column and 100 mM sodium phosphate (pH 7.2)/0.05% sodium azide as an elution buffer at 0.5 ml/min using an RI/DAWN-EOS detector.
  • carrier protein includes both small peptides and large polypeptides (>10 kDa).
  • the carrier protein can be any peptide or protein. It may include one or more T-helper epitopes.
  • the carrier protein is composed of tetanus toxoid (TT), fragment C of tetanus toxoid, diphtheria toxoid (DT), CRM197, pneumolysin (Ply), protein D, PhtD, PhtDE and N19. It can be selected from the group.
  • the carrier protein is CRM197.
  • CRM197 is used as the carrier protein.
  • CRM197 protein is a non-toxic variant of diphtheria toxin, immunologically indistinguishable from diphtheria toxin.
  • CRM197 is produced from a culture of Corynebacterium diphtheria strain C7 ( ⁇ 197) grown in media based on casamino acid and yeast extract.
  • CRM197 is purified through a combination of ultrafiltration, ammonium sulfate precipitation and ion exchange chromatography.
  • the carrier protein is tetanus toxoid (TT).
  • the inventors of the present invention believe that the serotype 23F polysaccharide activated by reacting with a specific molar equivalent of periodate in sodium acetate buffer or activated in 1 to 550 mM sodium acetate buffer is particularly stable in conjugate formation with the carrier protein and free It was confirmed that the incidence of polysaccharides and free proteins can be reduced. In the case of free protein, less than 1% was hardly produced. In particular, such stable conjugate formation can be obtained by using CRM197 as a carrier protein.
  • the method of the present invention may include mixing the activated serotype 23F polysaccharide with the carrier protein after step (iii).
  • the mixing step may include mixing the activated serotype 23F polysaccharide with the carrier protein after step (iii).
  • step (c) suspending the activated serotype 23F polysaccharide and carrier protein obtained in step (b) in a solvent.
  • any one sugar selected from sucrose, trehalose, raffinose, stachyose, mellegitose, dextran, mannitol, and lactitol, and activated serotype 23F and carrier protein are first mixed, In the presence of the sugar, polysaccharides and carrier proteins may be lyophilized.
  • the sugar contains sucrose.
  • the solvent may be a DMSO (dimethyl sulfoxide) solvent for the purposes of the present invention.
  • DMSO dimethyl sulfoxide
  • a mixture of activated serotype 23F polysaccharide and carrier protein may be mixed in a weight ratio of 1:0.1 to 5, and preferably, the weight ratio of activated serotype 23F polysaccharide: carrier protein is 1 May be :1.
  • step (v) after the polysaccharide and the carrier form a conjugate, the remaining unreacted carbonyl groups may be present, which may be capped using a suitable capping agent.
  • a capping agent may comprise sodium borohydride, for example, the product after step (v) is 15 minutes-15 hours, 15 minutes-45 minutes, 2-10 hours or 3- It can be reacted with sodium borohydride for 5 hours, about 30 minutes or about 4 hours.
  • capping is achieved by mixing the product of step (v) with about 0.8 to 0.12 molar equivalents of sodium borohydride.
  • the present invention may also include an additional step of purifying the conjugate, and diafiltration of the unreacted serotype 23F polysaccharide and carrier protein with 100 kDa ultrafiltration.
  • a method of preparing an immunogenic conjugate comprising a Streptococcus pneumoniae serotype 23F polysaccharide covalently bound to a carrier protein may have the following specific examples.
  • the purified serotype 23F polysaccharide was diluted with 1mM ⁇ 550mM sodium acetate (NaOAc) (pH4.5);
  • Resuspended activated serotype 23F polysaccharide and carrier protein are mixed 1:1 and reacted with sodium cyanoborohydride to generate serotype 23F polysaccharide:carrier protein conjugate;
  • it may be diluted with Deionized Water instead of sodium acetate of (1).
  • Another embodiment of the present invention provides a conjugated conjugate of Streptococcus pneumoniae serotype 23F and a carrier protein obtained by the method embodied by the present invention. It also provides an immunogenic composition comprising the conjugate.
  • Another embodiment of the present invention provides a conjugated conjugate of Streptococcus pneumoniae serotype 23F and a carrier protein obtained by the method embodied by the present invention. It also provides an immunogenic composition comprising the conjugate.
  • an “immunogenic composition” contains an antigen, such as a bacterial capsular polysaccharide or polysaccharide-protein conjugate, that has the ability to elicit an immune response mediated from a host, such as a mammal to a body fluid or to a cell or both.
  • the immunogenic composition can protect the host from infection by bacteria, can reduce its severity, or can protect the host from death due to bacterial infection. Immunogenic compositions can also be used to generate antibodies to a subject.
  • a conjugate of activated Streptococcus pneumoniae serotype 23F and CRM197 obtained by the above method, and an immunogenic composition comprising the same.
  • a conjugate of S. pneumoniae serotype 23F and CRM197 obtained by the above method of at least 300 kDa and an immunogenic composition comprising the same.
  • a conjugate of Streptococcus pneumoniae serotype 23F and CRM197 having a size of 250kDa to 400kDa obtained by the above method and an immunogenic composition comprising the same is provided.
  • the immunogenic composition of the present invention may contain a pharmaceutically acceptable additive and may contain a pharmaceutically acceptable excipient.
  • Additives or excipients included in the immunogenic composition may include examples commonly used in the industry.
  • the present invention also provides for use as a vaccine or vaccine against Streptococcus pneumoniae serotype 23F comprising the immunogenic composition of the present invention.
  • the vaccine may be administered through a vaccine administration route generally used for administration to a subject. It provides a use as a medicine for the treatment of Streptococcus pneumoniae serotype 23F infection comprising the immunogenic composition of the present invention.
  • the present invention can also prevent or treat pneumonia, meningitis, or bacteremia caused by Streptococcus pneumoniae serotype 23F by administering to an individual a conjugate in which Streptococcus pneumoniae serotype 23F is bound to a carrier protein.
  • Another embodiment of the present invention provides a method for activating a Streptococcus pneumoniae serotype 23F polysaccharide for the preparation of an immunogenic conjugate of a S. pneumoniae serotype 23F polysaccharide.
  • the method is to dilute Streptococcus pneumoniae serotype 23F polysaccharide purified by a conventional method with sodium acetate (NaOAc) (pH4.5), preferably sodium acetate at a concentration of 1 mM to 550 mM, and react with sodium periodate. And activating it.
  • the sodium periodate may contain a molar equivalent of 0.07 to 0.23, preferably 0.16 molar equivalent.
  • the inventors of the present invention obtained an activated polysaccharide that can be used in the conjugation process of the activated serotype 23F polysaccharide obtained using the method of the present invention, the degree of oxidation (Do), molecular weight, and yield were similar after activation, and as a result of conjugation, the polysaccharide/ It was confirmed that the properties of the conjugate were similar, such as protein ratio (PS/PR), free sugar (unconjugated polysaccharide, Free PS), size of the conjugate (MSD, MALLS), and yield.
  • PS/PR protein ratio
  • free sugar unconjugated polysaccharide, Free PS
  • MSD size of the conjugate
  • MALLS size of the conjugate
  • the activated 23F polysaccharide obtained by diluting and oxidizing purified serotype 23F polysaccharide using KH 2 PO 4 (pH 7.4) is 100 mM water for injection (WFI) regardless of the amount of sodium periodate added.
  • WFI water for injection
  • the activated serotype 23F polysaccharide molecular weight was 50 kDa or less, but in the case of the present invention, an activated 23F polysaccharide of at least 300 kDa or more could be obtained.
  • the effective concentration is limited to 10 mM, but sodium acetate (pH4.5) can obtain activated PS suitable for the purposes of the present invention in the range of 10 to 500 mM.
  • the present invention provides a vaccine of Streptococcus pneumoniae serotype 23F.
  • the conjugate of the present invention can induce immunity.
  • the present invention is to provide an optimal method for obtaining a size suitable for immunogenicity even if the polysaccharide size is reduced by treatment with an oxidizing agent.
  • the present invention provides a conjugate capable of preventing or treating diseases caused by Streptococcus pneumoniae serotype 23F.
  • S. pneumoniae culture and purification of capsular polysaccharide were performed by methods known to those skilled in the art.
  • S. pneumoniae serotype 23F can be obtained from various trustees and research institutes including ATCC (Strain: Spain 23F-1 [Sp264]).
  • ATCC Strain: Spain 23F-1 [Sp264]).
  • S. pneumoniae was identified as alpha hemolysis in capsular, non-motile, Gram-positive, lancet-shaped dicocci, and blood agar medium. The serotype was confirmed based on the Banlung test using a specific antisera (US Patent No. 5,847,112).
  • seed stocks were cultured for several generations (F1, F2 and F3 generations). Two additional generations of protozoa were cultured. Additional first generations were cultured from F3 vials, and subsequent generations were cultured from additional first generation vials.
  • a cryopreservative the seed vial was stored frozen together with synthetic glycerol (-70° C. or less).
  • synthetic glycerol -70° C. or less.
  • cell bank preparation all cultures were grown in soy-based medium. Before freezing, the cells were concentrated by centrifugation, the used medium was removed, and the cell pellet was resuspended in a fresh medium containing a cryopreservative (eg, synthetic glycerol).
  • a culture derived from the cell bank for production was used to inoculate a seed bottle containing a soybean-based medium.
  • a seed bottle was used to inoculate a seed fermentor containing a soy-based medium.
  • Fermentation was carried out in a seed fermenter while controlling temperature and pH. After reaching the target absorbance, it was inoculated into a production fermentor containing a soy-based medium.
  • Production culture is the final step in fermentation. The temperature, pH and stirring speed were adjusted.
  • the culture broth was centrifuged and filtered to remove bacterial cell debris. Impurities were removed and the capsular polysaccharide was purified using several concentration/diafiltration operations, precipitation/elution and multi-layer filtration.
  • the serotype 23F polysaccharide was activated and conjugated to CRM197.
  • the activation process involves reducing the size of the capsular polysaccharide to a target molecular weight, chemically activating it, and buffer exchange through ultrafiltration.
  • Purified CRM197 is conjugated with activated polysaccharide, and the conjugate is purified using ultrafiltration and finally filtered through a 0.22 ⁇ m filter. Process parameters such as pH, temperature, concentration and time are as described below.
  • Each serotype polysaccharide was diluted with water for injection and sodium acetate so that the final concentration range was 1.0 to 2.0 mg/mL.
  • the final concentration of the sodium acetate buffer was 0.5mM, 10mM, 120mM, 150mM, 180mM, 200mM, 300mM and 500mM.
  • Sodium periodate required for serotype 23F polysaccharide activation was 0.16 molar equivalent to the polysaccharide content. While thoroughly mixing, the oxidation reaction proceeded for 16 to 20 hours at room temperature (21-25°C).
  • the activated serotype 23F polysaccharide was concentrated with a 100 kDa MWCO ultrafiltration filter and diafiltered with 0.01M sodium acetate buffer (pH 4.5). The permeate was discarded and the residue was filtered through a 0.22 ⁇ m filter.
  • Step 4 freeze drying
  • Lyophilized activated sugar serotype 23F and lyophilized CRM197 carrier protein were equilibrated at room temperature and resuspended in DMSO.
  • Activated saccharide and CRM197 carrier protein were mixed in a ratio ranging from 0.8 to 1.25 g saccharide/g CRM197.
  • the conjugation reaction was initiated by adding a sodium cyanoborohydride solution (100 mg/mL) in a ratio of 0.8 to 1.2 molar equivalents of sodium cyanoborohydride to 1 mole of activated saccharide. Water for injection at a target concentration of 1% (v/v) was added to the reaction mixture and the mixture was incubated at 23° C. ⁇ 2° C. for 24 hours.
  • the diluted conjugation mixture was concentrated and diafiltered on a 100 kDa MWCO ultrafiltration filter using at least 20 volumes of 0.9% sodium chloride or buffer. The permeate was discarded.
  • Step 4 sterile filtration
  • the residual liquid after diafiltration of 100 kDa MWCO was filtered through a 0.22 ⁇ m filter.
  • the filtered product 23F-CRM197 conjugate was subjected to control (sugar content, free protein, free sugar, residual cyanide and residual DMSO) during the manufacturing process.
  • the filtered residue was subjected to in-process control to determine whether additional concentration, diafiltration and/or dilution were required. If necessary, the filtered conjugate was diluted with 0.9% sodium chloride to a final concentration of less than 0.55 g/L. At this stage, glass tests were conducted for sugar content, protein content and sugar:protein ratio.
  • the conjugate was filtered (0.22 ⁇ m) and subjected to a free test (appearance, free protein, free sugar, endotoxin, molecular size determination, residual cyanide, residual DMSO, sugar identity and CRM197 identity).
  • the final conjugate concentrate was stored refrigerated at 2 to 8°C.
  • the required amount of the final stock solution was calculated based on the batch volume and the serotype 23F conjugate saccharide concentration.
  • the required amount of 0.85% sodium chloride (physiological saline), polysorbate 80, and succinate buffer were added to the previously labeled formulation container, followed by the addition of the conjugate concentrate. Mix thoroughly and filter through 0.22 ⁇ m filter. After the addition of aluminum phosphate, the formulated final liquid was slowly mixed. The formulated product was stored at 2-8°C.
  • the resulting vaccine composition contained 2 ⁇ g of saccharide, about 2.5 ⁇ g of CRM197 carrier protein in a total of 0.5 mL; 0.125 mg elemental aluminum (0.5 mg aluminum phosphate) adjuvant; About 4.25 mg sodium chloride; About 295 ⁇ g of succinate buffer; And about 100 ⁇ g of polysorbate 80.
  • Serum was analyzed by OPA assay to evaluate the function of the antibody. The same amount of serum was taken for each individual and diluted 10-fold. Using opsonization buffer, 10uL of S. pneumoniae diluted appropriately diluted with 20 uL of serial dilution (step dilution) serum was mixed and reacted at room temperature for 30 minutes. To the serum-S. pneumoniae reaction solution, a mixture of previously differentiated HL-60 cells and complement was added and reacted in a CO 2 incubator (37° C.) for 45 minutes. The temperature was lowered to stop phagocytosis, and 10 ⁇ L of the reaction solution was plated on dried THY agar medium for 30 to 60 minutes in advance.
  • the THY agar medium containing TTC was additionally overlaid. Incubated for 12 to 18 hours in a CO 2 incubator (37° C.) and the number of clusters was counted. OPA titer was expressed as the dilution factor at which 50% killing was observed. The results are shown in Table 3 below.
  • Conjugates (groups 3 and 4) prepared by activating polysaccharides of serotype 23F at a buffer concentration of 10 mM or 150 mM showed significantly higher MOPA titers than conjugates (groups 1 and 2) activated at a buffer concentration of DW or 0.5 mM. .
  • the present invention can be used as a pneumococcal vaccine.
  • the present invention can be provided as a drug for preventing pneumococcal infection.

Abstract

La présente invention concerne un procédé de production d'un conjugué du sérotype 23F de Streptococcus pneumoniae et d'une protéine porteuse, le procédé comprenant : (I) une étape de mélange d'un polysaccharide capsulaire du sérotype 23F de Streptococcus pneumoniae (S. pneumoniae) purifié avec une solution tampon d'acétate de sodium (NaOAc) pour obtenir un mélange ; (ii) une étape de mise en réaction du mélange avec un agent oxydant pour produire un polysaccharide du sérotype 23F activé ; (iii) une étape de filtration du polysaccharide du sérotype 23F activé avec de l'acétate de sodium pour sélectionner un polysaccharide du sérotype 23F activé ayant au moins 300 kDa ; (iv) une étape de mélange du polysaccharide du sérotype 23F activé avec une protéine porteuse ; et (v) une étape d'addition d'un agent réducteur à un mélange du polysaccharide du sérotype 23F activé et de la protéine porteuse, et de conjugaison de celui-ci pour former un conjugué du polysaccharide du sérotype 23F activé et de la protéine porteuse. La présente invention peut fournir un conjugué hautement immunogène dans lequel la taille d'un polysaccharide capsulaire du sérotype 23F de Streptococcus pneumoniae (S. Pneumoniae) peut être maintenue constante.
PCT/KR2020/006863 2019-05-28 2020-05-27 Procédé de production d'un conjugué immunogène du sérotype 23f de streptococcus pneumoniae WO2020242199A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2019-0062757 2019-05-28
KR1020190062757A KR20200136756A (ko) 2019-05-28 2019-05-28 스트렙토코커스 뉴모니애 혈청형 23f의 면역원성 접합체 제조방법

Publications (1)

Publication Number Publication Date
WO2020242199A1 true WO2020242199A1 (fr) 2020-12-03

Family

ID=73554136

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2020/006863 WO2020242199A1 (fr) 2019-05-28 2020-05-27 Procédé de production d'un conjugué immunogène du sérotype 23f de streptococcus pneumoniae

Country Status (2)

Country Link
KR (1) KR20200136756A (fr)
WO (1) WO2020242199A1 (fr)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20090094163A (ko) * 2006-12-22 2009-09-03 와이어쓰 다가 폐렴구균 다당류-단백질 접합체 조성물
KR20130142574A (ko) * 2012-06-20 2013-12-30 에스케이케미칼주식회사 다가 폐렴구균 다당류-단백질 접합체 조성물
KR20180043122A (ko) * 2016-10-19 2018-04-27 동국대학교 산학협력단 신규링커를 통한 폐렴구균 다당류-단백질 접합체 백신 및 이의 용도
KR20180046893A (ko) * 2016-10-28 2018-05-09 주식회사 엘지화학 향상된 IgG 역가를 갖는 다가면역원성 조성물 및 이의 용도
KR20180120482A (ko) * 2017-04-27 2018-11-06 주식회사 유바이오로직스 스트렙토코커스 뉴모니아 협막 다당체의 생산방법

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20090094163A (ko) * 2006-12-22 2009-09-03 와이어쓰 다가 폐렴구균 다당류-단백질 접합체 조성물
KR20130142574A (ko) * 2012-06-20 2013-12-30 에스케이케미칼주식회사 다가 폐렴구균 다당류-단백질 접합체 조성물
KR20180043122A (ko) * 2016-10-19 2018-04-27 동국대학교 산학협력단 신규링커를 통한 폐렴구균 다당류-단백질 접합체 백신 및 이의 용도
KR20180046893A (ko) * 2016-10-28 2018-05-09 주식회사 엘지화학 향상된 IgG 역가를 갖는 다가면역원성 조성물 및 이의 용도
KR20180120482A (ko) * 2017-04-27 2018-11-06 주식회사 유바이오로직스 스트렙토코커스 뉴모니아 협막 다당체의 생산방법

Also Published As

Publication number Publication date
KR20200136756A (ko) 2020-12-08

Similar Documents

Publication Publication Date Title
WO2013191459A1 (fr) Composition de conjugués polysaccharide de pneumocoque-protéine polyvalents
CN109862908B (zh) 多价肺炎球菌多糖-蛋白质缀合物组合物
JP6950099B2 (ja) 多価肺炎球菌多糖体−タンパク質複合体組成物
EA023059B1 (ru) Способ конъюгирования бактериальных полисахаридов с белками-носителями
WO2014092378A1 (fr) Composition d'un conjugué polysaccharide-protéine pneumococcique multivalent
WO2014092377A1 (fr) Composition d'un conjugué polysaccharide-protéine pneumococcique multivalent
JP2021512870A (ja) 多価肺炎球菌多糖体−タンパク質複合体組成物
WO2018169303A1 (fr) Composition vaccinale polyvalente contre streptococcus pneumoniae
KR20090094163A (ko) 다가 폐렴구균 다당류-단백질 접합체 조성물
TW201811362A (zh) 多價肺炎球菌多醣-蛋白質共軛物組成物(一)
KR20090096731A (ko) 다가 폐렴구균 다당류-단백질 접합체 조성물
WO2021010798A1 (fr) Composition immunogène comprenant des conjugués multivalents protéine- polysaccharide de streptococcus pneumoniae
CN114728050A (zh) 多价肺炎球菌多糖-蛋白质缀合物组合物及其使用方法
KR20140145941A (ko) 컨쥬게이션 방법
JP2022513562A (ja) 肺炎連鎖球菌の精製された莢膜多糖
US20220143166A1 (en) Multivalent pneumococcal polysaccharide-protein conjugate vaccine
WO2018048141A1 (fr) Composition comprenant une protéine multivalent de transport de polysaccharide capsulaire et son utilisation
WO2020157772A1 (fr) Compositions vaccinales à base de conjugués polysaccharide-protéine pneumococcique multivalentes
WO2020009462A1 (fr) Composition immunogène multivalente comprenant des conjugués polysaccharide-protéine et vaccin la comprenant pour prévenir une maladie provoquée par streptococcus pneumoniae
WO2018080213A1 (fr) Composition immunogène multivalente ayant un titre d'igg augmenté, et son utilisation
WO2020242199A1 (fr) Procédé de production d'un conjugué immunogène du sérotype 23f de streptococcus pneumoniae
RU2260053C2 (ru) Способ выделения биологически активной фракции (баф), содержащей s-липополисахариды (s-лпс) из грамотрицательных бактерий, баф для лечения и профилактики заболеваний, вызываемых грамотрицательными бактериями, производящими эндотоксичные s-лпс, фармацевтическая композиция, способы индукции протективного иммунитета и улучшения состояния пациента при состояниях, требующих повышения иммунного статуса
WO2023003329A1 (fr) Composition vaccinale comprenant un conjugué polysaccharide-protéine capsulaire dérivé de salmonella typhi
KR102028693B1 (ko) 스트렙토코커스 뉴모니아 협막 다당체의 생산방법
KR20200005458A (ko) 다가 폐렴구균 다당체-단백질 접합체를 포함하는 면역원성 조성물, 및 이를 포함하는 약학 조성물

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20814515

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 20814515

Country of ref document: EP

Kind code of ref document: A1